Precigen is a cash-burning biotech with a dangerously weak quality profile, but extreme momentum signals and analyst upside of 159% suggest a speculative setup with limited near-term downside if short-interest pressure resolves.
Thesis pillars
- Cash Burn Quality Floor Breach→Stable
- High Short Interest Risk↑Improving
- Momentum Technical Breakout↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 25, 2026· older than 90 days
Precigen, Inc. (PGEN) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $5.25: Concentration risk — Product: Papzimeos; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting... Read more
Sell if holding. Multiple concerning factors at $5.25: Concentration risk — Product: Papzimeos; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0). Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Score 5.0/10, high confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
Recent developments
updated Nov 2, 2026Recent Developments — Precigen, Inc.
Latest news
- NEWS Precigen (PGEN) Shares Drop 25% After Inovio's FDA Nod for Compe - GuruFocus — GuruFocus Nov 2, 2026 negative
- NEWS Precigen Shares Decline Following Approval of Rival RRP Treatment — fiscal.ai Nov 2, 2026 negative
- NEWS Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market — benzinga Nov 2, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Monday's Pre-Market Session — benzinga Nov 2, 2026 neutral
- NEWS Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket — benzinga Nov 2, 2026 positive
Latest item Nov 2, 2026 · Generated 2026-11-04T12:04:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPapzimeos10-K Item 1A: 'Our near-term prospects, including our ability to develop our product candidates and generate revenue, and our future growth are substantially dependent on the commercial success of Papzimeos.'
Material Events(8-K, last 90d)
- 2026-06-24Item 5.02LOWStockholders approved an amendment to the 2023 Omnibus Incentive Plan at the June 18, 2026 Annual Meeting, increasing shares available for issuance by 7 million. Routine compensatory plan amendment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $5.25: Concentration risk — Product: Papzimeos; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0). Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Prior stop was $4.88. Score 5.0/10, high confidence.
Analyst target: $11.60 (+121.0% upside). Prior stop was $4.88. Stop-loss: $4.88.
Concentration risk — Product: Papzimeos; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0); Leverage penalty (D/E 2.3): -1.5.
Precigen, Inc. trades at a P/E of N/A (forward -23.9). TrendMatrix value score: 5.4/10. Verdict: Sell.
10 analysts rate PGEN, with a consensus score of 4.0/5. 3 analysts publish price targets averaging $14.
What does Precigen, Inc. do?Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using...
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.